Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial-Reference-Cited by-同舟云学术

Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial

Published:2022-09 Issue: Volume:173 Page:317-326
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Carles Joan,Alonso-Gordoa Teresa,Mellado Begoña,Méndez-Vidal María J.,Vázquez Sergio,González-del-Alba Aránzazu,Piulats Josep M.,Borrega Pablo,Gallardo Enrique^ORCID,Morales-Barrera Rafael,Paredes Pilar,Reig Oscar^ORCID,Garcías de España Carmen,Collado Ricardo^ORCID,Bonfill Teresa,Suárez Cristina,Sampayo-Cordero Miguel^ORCID,Malfettone Andrea,Garde Javier

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference44 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA: A Cancer J Clinic,2021

2. Prognostic significance of young age and non-bone metastasis at diagnosis in patients with metastatic prostate cancer: a SEER population-based data analysis;Guo;J Cancer,2019

3. Cancer statistics, 2021. CA;Siegel;A Cancer Journal for Clinicians,2021

4. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients;Bubendorf;Hum Pathol,2000

5. Androgen receptor splice variant, AR-V7, as a biomarker of resistance to androgen axis-targeted therapies in advanced prostate cancer;Zhang;Clin Genitourin Cancer,2020

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of interventions for metastatic castration resistant prostate cancer (mCRPC) patients progressing on androgen receptor-axis-targeted (ARAT) therapy: a systematic literature review;Current Medical Research and Opinion;2024-08-27

2. Quantitative single-photon emission computed tomography/computed tomography in assessing the effectiveness of radium-223 dichloride therapy;Cancer Urology;2024-08-15

3. Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer;Frontiers in Oncology;2024-05-07

4. Second-line treatment options in metastatic castration-resistant prostate cancer after progression on first-line androgen-receptor targeting therapies: A systematic review and Bayesian network analysis;Critical Reviews in Oncology/Hematology;2024-04

5. Case report: Exceptional and durable response to Radium-223 and suspension of androgen deprivation therapy in a metastatic castration-resistant prostate cancer patient;Frontiers in Oncology;2024-03-08